ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of0.39 m2 and above:To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)• For the treatment of processing-deficient Progeroid Laminopathies with either:o Heterozygous LMNA mutation with progerin-like protein accumulationo Homozygous or compound heterozygous ZMPSTE24 mutationsLimitations of UseZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.